Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMB8 | P28062 | 15/20 | 1.00 |
| ▸ | PSMB11 | A5LHX3 | 2/20 | 0.53 |
| ▸ | PSMD11 | O00231 | 2/20 | 0.53 |
| ▸ | PSMD12 | O00232 | 2/20 | 0.53 |
| ▸ | PSMD14 | O00487 | 2/20 | 0.53 |
| ▸ | PSMA7 | O14818 | 2/20 | 0.53 |
| ▸ | PSMD3 | O43242 | 2/20 | 0.53 |
| ▸ | PSMC3 | P17980 | 2/20 | 0.53 |
| ▸ | PSMB1 | P20618 | 2/20 | 0.53 |
| ▸ | PSMA1 | P25786 | 2/20 | 0.53 |
| ▸ | PSMA2 | P25787 | 2/20 | 0.53 |
| ▸ | PSMA3 | P25788 | 2/20 | 0.53 |
| ▸ | PSMA4 | P25789 | 2/20 | 0.53 |
| ▸ | PSMB9 | P28065 | 2/20 | 0.53 |
| ▸ | PSMA5 | P28066 | 2/20 | 0.53 |
| ▸ | PSMB4 | P28070 | 2/20 | 0.53 |
| ▸ | PSMB6 | P28072 | 2/20 | 0.53 |
| ▸ | PSMB5 | P28074 | 2/20 | 0.53 |
| ▸ | PSMC2 | P35998 | 2/20 | 0.53 |
| ▸ | PSMB10 | P40306 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14755644 | 0.96 | PSMB8 (1.00) | PSMB8PSMB11PSMD11PSMD12PSMD14 | |
| SCHEMBL14755434 | 0.82 | PSMB8 (0.69) | PSMB8PSMB11PSMD11PSMD12PSMD14 | |
| SCHEMBL12614772 | 0.80 | PSMB8 (0.68) | PSMB8PSMB11PSMD11PSMD12PSMD14 | |
| SCHEMBL9627131 | 0.80 | PSMB8 (0.68) | PSMB8PSMB11PSMD11PSMD12PSMD14 | |
| SCHEMBL459541 | 0.80 | PSMB8 (0.68) | PSMB8PSMB11PSMD11PSMD12PSMD14 | |
| SCHEMBL16363828 | 0.80 | PSMB8 (0.68) | PSMB8PSMB11PSMD11PSMD12PSMD14 | |
| SCHEMBL18614390 | 0.80 | PSMB8 (0.68) | PSMB8PSMB11PSMD11PSMD12PSMD14 | |
| SCHEMBL1781945 | 0.80 | PSMB8 (0.68) | PSMB8PSMB11PSMD11PSMD12PSMD14 | |
| SCHEMBL2730784 | 0.80 | PSMB8 (0.66) | PSMB8PSMB11PSMD11PSMD12PSMD14 | |
| SCHEMBL11396664 | 0.78 | PSMB8 (0.69) | PSMB8PSMB11PSMD11PSMD12PSMD14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 104 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200392259-A1 | ORTHOMETALLATED CATALYST COMPONENTS FOR OLEFIN POLYMERIZATION AND COPOLYMERIZATION | ARZOUMANIDIS GREGORY G (US) | 2020-12-17 | — | — | US | claimed |
| US-20110118274-A1 | PROTEASOME INHIBITORS AND THEIR USE IN TREATING PATHOGEN INFECTION AND CANCER | CORNELL RESEARCH FOUNDATION, INC. (US) | 2011-05-19 | — | — | US | claimed |
| US-12565492-B2 | Anaplastic Lymphoma Kinase (ALK) degraders and uses thereof | TRIANA BIOMEDICINES, INC. (US) | 2026-03-03 | — | — | US | disclosed |
| US-20260042752-A1 | ANAPLASTIC LYMPHOMA KINASE (ALK) DEGRADERS AND USES THEREOF | TRIANA BIOMEDICINES INC (US) | 2026-02-12 | — | — | US | disclosed |
| US-12433895-B2 | Therapeutically active compounds and their methods of use | SERVIER PHARMACEUTICALS LLC (US) | 2025-10-07 | — | — | US | disclosed |
| US-20240335448-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | PHARMARESROUCES (SHANGHAI) CO., LTD. (CN) | 2024-10-10 | — | — | US | disclosed |
| US-11844758-B2 | Therapeutically active compounds and their methods of use | SERVIER PHARMACEUTICALS LLC (US) | 2023-12-19 | — | — | US | disclosed |
| CN-111087353-B | Therapeutically active compounds and methods of use thereof | 法国施维雅药厂 | 2023-10-24 | — | — | CN | disclosed |
| US-20220354856-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | SERVIER PHARMACEUTICALS LLC | 2022-11-10 | — | — | US | disclosed |
| US-11339130-B1 | Calpain modulators and therapeutic uses thereof | BLADE THERAPEUTICS, INC. (US) | 2022-05-24 | — | — | US | disclosed |
| US-10946023-B2 | Therapeutically active compounds and their methods of use | AGIOS PHARMACEUTICALS, INC. (US) | 2021-03-16 | — | — | US | disclosed |
| US-6103898-A | REACTING ACYCLIC UREA DERIVATIVE WITH A DIKETONE, SUBSEQUENT CATALYTIC HYDROGENATION TO FORM CYCLIZED POLAR APROTIC SOLVENT | BASF AKTIENGESELLSCHAFT (DE) | 2000-08-15 | — | — | US | disclosed |
| EP-0906905-A1 | Process for the preparation of cyclic ureas | BASF AKTIENGESELLSCHAFT (DE) | 1999-04-07 | — | — | EP | disclosed |
| US-4544752-A | TREATMENT OF GOUT; ANTIARTHRITIC AGENTS | ELI LILLY AND COMPANY (US) | 1985-10-01 | — | — | US | disclosed |
| EP-0048615-B1 | IMPROVEMENTS IN OR RELATING TO 3-ARYL-5-ISOTHIAZOLE DERIVATIVES | ELI LILLY AND COMPANY (US) | 1984-05-30 | — | — | EP | disclosed |
| US-4346094-A | ENZYME INHIBITORS | ELI LILLY AND COMPANY (US) | 1982-08-24 | — | — | US | disclosed |
| EP-0048615-A1 | Improvements in or relating to 3-aryl-5-isothiazole derivatives | ELI LILLY AND COMPANY (US) | 1982-03-31 | — | — | EP | disclosed |
| US-4261728-A | PREEMERGENT ACTIVITY | MONSANTO COMPANY (US) | 1981-04-14 | — | — | US | disclosed |
| US-4187099-A | 3-Aryl-4-isothiazolecarboxylic acid and 3-aryl-4-isoxazolecarboxylic acid derivatives and their use as herbicides | MONSANTO COMPANY (US) | 1980-02-05 | — | — | US | disclosed |
| US-4144047-A | SOYBEANS | MONSANTO COMPANY (US) | 1979-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12433895-B2 | Therapeutically active compounds and their methods of use | MCL1, TP53, BRDT | PSMB8 4114/4885PSMB11 4007/4885PSMD11 4042/4885 |
| US-20260042752-A1 | ANAPLASTIC LYMPHOMA KINASE (ALK) DEGRADERS AND USES THEREOF | ALK, NTRK1, NTRK3 | PSMB8 3466/4885PSMB11 3724/4885PSMD11 1412/4885 |
| US-11844758-B2 | Therapeutically active compounds and their methods of use | MCL1, TP53, BRDT | PSMB8 4114/4885PSMB11 4007/4885PSMD11 4042/4885 |
| US-11339130-B1 | Calpain modulators and therapeutic uses thereof | CAPNS1, CAPN9, CAPN1 | PSMB8 338/4885PSMB11 335/4885PSMD11 195/4885 |
| US-20240335448-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | MCL1, TP53, BRDT | PSMB8 4114/4885PSMB11 4007/4885PSMD11 4042/4885 |
| US-10946023-B2 | Therapeutically active compounds and their methods of use | MCL1, TP53, BRDT | PSMB8 4114/4885PSMB11 4007/4885PSMD11 4042/4885 |
| US-20110118274-A1 | PROTEASOME INHIBITORS AND THEIR USE IN TREATING PATHOGEN INFECTION AND CANCER | PSMB1, PSME1, PSMB2 | PSMB8 22/4885PSMB11 7/4885PSMD11 31/4885 |
| US-12565492-B2 | Anaplastic Lymphoma Kinase (ALK) degraders and uses thereof | ALK, NTRK3, NTRK1 | PSMB8 3811/4885PSMB11 4230/4885PSMD11 1798/4885 |
| US-20220354856-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | MCL1, TP53, BRDT | PSMB8 4114/4885PSMB11 4007/4885PSMD11 4042/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.